DnB Asset Management’s UroGen Pharma URGN Stock Holding History

DnB Asset Management’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$475K	Sell	12,906 -568	-4%	-$15.4K	﹤0.01%	817
2026 Q1	$242K	Sell	13,474 -3,487	-21%	-$69.9K	﹤0.01%	1065
2025 Q4	$397K	Buy	+16,961	New	+$368K	﹤0.01%	686

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

DnB Asset Management's URGN Position: Q2 2026 in Review

DnB Asset Management reduced its UroGen Pharma (URGN) stake by 4.2% in Q2 2026, selling an estimated $15.4K and leaving 12,906 shares worth $475K. The position accounts for ﹤0.01% of the portfolio, ranked #817.

DnB Asset Management first reported a position in URGN in Q4 2025 and has held it in 3 quarters since. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

DnB Asset Management held 12,906 shares of UroGen Pharma worth $475K as of Q2 2026.
DnB Asset Management sold 568 UroGen Pharma shares in Q2 2026, an estimated $15.4K.
UroGen Pharma made up ﹤0.01% of DnB Asset Management's portfolio in Q2 2026, its #817 holding.
DnB Asset Management first reported a position in UroGen Pharma in Q4 2025 and has held it in 3 quarters since.
189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on DnB Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.